Klimentina G.
- Country
- Bulgaria
- Department
- NA
Research Overview
- A Phase 2 Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of LAD328 in Adults with Moderate to Severe Hidradenitis Suppurativa
- Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Trial Evaluating Lutikizumab Efficacy and Safety in Moderate to Severe Hidradenitis Suppurativa
- A multicenter, randomized, participant- and investigator -blinded, placebo-controlled, phase 2a study to assess the efficacy, safety and tolerability of GIA632 in adult participants with moderate to severe atopic dermatitis
Data & Insights
Has run more than one trial at 14 of 131 partner sites.
Specializations
Inflammatory Skin Disease
Klimentina Gospodinova’s clinical research activity is centered on atopic dermatitis, hidradenitis suppurativa, and moderate to severe plaque psoriasis, with additional involvement in non-segmental vitiligo. The therapeutic focus includes immune-mediated dermatologic conditions requiring systemic treatment and symptom control.
- Atopic dermatitis
- Hidradenitis suppurativa
- Plaque psoriasis
- Vitiligo
The investigator is involved in studies evaluating advanced dermatology therapies for both chronic inflammatory skin disease and difficult-to-treat cutaneous inflammation.
Hidradenitis Suppurativa Therapy
A major area of interest is hidradenitis suppurativa across adult and adolescent populations, including moderate to severe hidradenitis suppurativa. The research landscape reflects a strong therapeutic emphasis on symptom reduction, disease control, and sustained management of this debilitating inflammatory disorder.
- Moderate to severe hidradenitis suppurativa
- Long-term disease management
- Inflammation-driven skin disease
Her trial involvement spans multiple investigational approaches in hidradenitis suppurativa, highlighting a sustained focus on treatment options for persistent and recurrent skin inflammation.
Cardiovascular Risk and Hypertension
Her clinical interests also extend to atherosclerotic cardiovascular disease and difficult-to-control blood pressure disorders, including uncontrolled hypertension and resistant hypertension. These studies reflect a focus on cardiometabolic risk reduction and blood pressure regulation in patients with persistent cardiovascular disease burden.
- Atherosclerotic cardiovascular disease
- Uncontrolled hypertension
- Resistant hypertension
The investigator’s participation in this area connects cardiovascular prevention with management of treatment-refractory hypertension.
Neurologic Symptom Management
Another therapeutic area of involvement is Parkinson’s disease with apathy. This research interest is oriented toward neurologic symptom burden and the treatment of non-motor manifestations that affect daily functioning and quality of life.
- Parkinson’s disease
- Apathy
The investigator’s work in this field supports clinical evaluation of therapies aimed at addressing motivational and behavioral symptoms in neurodegenerative disease.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.